Please assess the completion status of the following clinical trial:

Trial Title: A 6 Month Study to Compare the Metabolic Effects of Paliperidone ER and Olanzapine in Patients With Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient meets the DSM-IV criteria for schizophrenia~* Patient has a PANSS total score at screening of 60 to 100, inclusive~* Patient must, in the opinion of the investigator, benefit from treatment with paliperidone ER or olanzapine~* Patients on lipid-lowering therapy must be on a stable dose for at least 4 weeks for statins, niacin, ezetimibe and resins or for at least 12 weeks for fibrates~* Female patients must be postmenopausal (for at least 1 year), surgically sterile, abstinent, or, if sexually active, be practicing and effective method of birth control (e.g. prescription oral contraceptives, contraceptive injections, intrauterine device, double-barrier method, contraceptive patch, male partner sterilization) before entry and throughout the study~* Women of child-bearing potential must have a negative urine pregnancy test at screening~* Patient is healthy on the basis of a physical examination and vital signs at screening~Exclusion Criteria:~* Patient has previously been treated with paliperidone ER, olanzapine, or clozapine within the past 6 months or has never been treated with an antipsychotic before~* Treatment with a depot antipsychotic within the past 3 months~* Treatment with a mood stabilizer or a recently initiated antidepressant (\<= 3 months)~* Patient has abnormal fasting plasma glucose (\> 126 mg/dL) or fasting triglycerides (TG) levels (\> 400 mg/dL) at screening~* Relevant history of any significant and/or unstable cardiovascular, respiratory, neurologic (including seizures or significant cerebrovascular), renal, hepatic, endocrine, or immunologic diseases, including recent or present clinically relevant laboratory abnormalities (as deemed by the investigator)~* History or current symptoms of tardive dyskinesia~* History of neuroleptic malignant syndrome~* Pregnant or breast-feeding female

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 001 (Type: EXPERIMENTAL): paliperidone ER 6-mg or 9-mg tablet once daily flexible dosing for 6 months
- 002 (Type: ACTIVE_COMPARATOR): olanzapine 10-15 mg (using 5-mg or 10-mg tablets) once daily flexible dosing for 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).